Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

June 30, 2011 Approval Letter - Fluvirin 2011/2012 Formulation

Our STN:   BL 103837/5571                    

Novartis Vaccines and Diagnostics Limited
Attention: Dr. Joanne Totosy de Zepetnek, PhD
350 Massachusetts Avenue
Cambridge, MA 02139-4182
Dear Dr. Totosy de Zepetnek:
We have approved your request to supplement your Biologics License Application for Influenza Virus Vaccine, (Fluvirin®), to include the 2011-2012 United States formulation.
Please submit all final printed labeling at the time of use and include implementation information on Form FDA 356h. Please provide your final content of labeling in Structured Product Labeling (SPL) format and include the carton and container labels.  
We will include information contained in the above-referenced supplement in your Biologics License Application file.
Sincerely yours,
Jerry P. Weir, Ph.D.
Division of Viral Products
Office of Vaccines
 Research and Review
Center for Biologics
 Evaluation and Research

Resources for You

Page Last Updated: 07/05/2011
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English